AstraZeneca's P2T antagonist AR-C69931MX beneficial and safe for acute coronary syndromes March 15, 2000
Bivalirudin versus heparin during PTCA: six-month outcomes favor bivalirudin in post-MI patients March 14, 2000
RSS